Pfizer Building Viagra As Pan-European Consumer Health Brand With Rx-To-OTC Switch In Norway
Executive Summary
Pfizer has taken the first steps towards turning its Viagra erectile dysfunction treatment into a pan-European OTC brand by taking advantage of Norway's new "non-prescription medicines with guidance" category to secure the Rx-to-OTC switch of the product. Norway will be the second European market where Viagra is available OTC after the UK switched the drug in 2017.
You may also be interested in...
Sanofi Secures First EU Market Approval for OTC Cialis
Following an application through the decentralised procedure, Ireland is the first EU member state to approve Sanofi's Cialis (tadalafil) for non-prescription sale. An OTC version of the blockbuster erectile dysfunction treatment has also been given the green light in Norway, but Germany has rejected the product.
Why Did Germany’s Switch Experts Reject OTC Tadalafil And Sildenafil (Again)?
Germany's Expert Committee for Prescription has once again rejected the OTC switch of sildenafil, as well as tadalafil. The recently published full meeting minutes show key concerns were falsification, misuse and OTC pricing.
Why Did Germany Reject Sildenafil OTC Switch?
Sildenafil was rejected at Germany’s independent switch committee’s most recent meeting. HBW Insight examines some of the arguments for and against the switch put forward by the regulator, members of the committee and the applicant, as recorded in the recently published minutes.